Abstract Search

ea0063gp139 | Obesity | ECE2019

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

Luzi Livio , Raben Anne , Astrup Arne , Matejkova Erika , Svacina Stepan , Gnessi Lucio , Navas-Carretero Santiago , Martinez J Alfredo , Greenway Frank , Aronne Louis , Apovian Caroline , Kaplan Lee , Hill James , Fujioka Ken , Still Christopher , Sannino Alessandro , Saponaro Cosimo , Calderon Henry , Urban Lorien , Chiquette Elaine , Leider Harry , Ron Eyal , Zohar Yishai , Heshmati Hassan

Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...

0 shares

Endocrine Abstracts

Prediction of clinically significant weight loss with Gelesis100 in the GLOW study as early as 8 weeks post-treatment

BiosciAbstracts